

Media Release

5 September 2007

Actelion awards grants to young investigators for innovative clinical endothelin research

VIENNA - 4 September 2007 - Actelion announced today the three winners of the Actelion Endothelin Research Awards (AERA) program which supports young clinical scientists involved in endothelin research related to heart, lung and vascular diseases. The clinical research grants have been awarded to three physicians in Austria and France.

A total of 42 applications were received from 15 countries, and grants were awarded by the AERA Steering Committee. The winning applications were selected based on scientific excellence, originality, feasibility and relevance to the purpose of the program.

The award winners and the supported projects are:

- **Dr Christopher Adlbrecht**, Medical University of Vienna, Austria
"Active endothelin in pulmonary embolism"
- **Dr Sandrine Launois-Rollinat**, University Joseph Fourier, Grenoble, France
"Cardiovascular consequences of obstructive sleep apnea: role of endothelin and preventive effects of bosentan"
- **Dr David Montani**, Hôpital Antoine Bécélère, Clamart, France
"Endothelin receptor antagonism and dendritic cells function in pulmonary arterial hypertension"

Professor Damien Bonnet, from the French Reference Center for Complex Congenital Heart Defects in Paris, one of the members of the Steering Committee, comments: "The standard of entries for the awards this year has been impressive - with many high-quality, innovative research projects. This is reassuring as the exploration in new research areas will allow us to better understand the role of endothelin in a variety of conditions, and will increase our knowledge of how to best approach related diseases".

The AERA program was established in 2006 as a mentored and grant-based program targeting young investigators at universities and research institutes with an interest in

clinical endothelin research. Results from the projects awarded in July 2006 will be available in 2008.

Applications are assessed by an independent board of renowned experts in endothelin research, the AERA Steering Committee. The second competition cycle was launched on 15 January 2007 and submissions were accepted from March 2007 for three months.

Eligible applicants were invited to submit a Letter of Intent via the AERA website, followed by a period of assessment by the committee. Eight applicants were invited to submit a full proposal within 4 weeks. Grants of up to 65,000 Euros are available for projects with a maximum of twelve months for completion. For further information about the AERA please visit: www.endothelin.org.

- ends -

Notes to editors:

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer[®], an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer[®] through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union as well as Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).

For further information please contact:

Actelion Ltd, Gewerbestrasse 16, CH-4123 Allschwil

Actelion contact	Marc Urich, Senior Clinical Scientist	+41 61 565 5283 marc.urich@actelion.com
Media contacts	Michelle Powell (Packer Forbes) Packer Forbes	+ 44 7809 363 011 + 44 208 772 1551 tracleer-pr@packerforbes.com

<http://www.actelion.com>